CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
We received an updated WNV package insert; please note the manufacturer and license number has been ...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...